Novo Nordisks senior VP, Anna Windle, highlighted that their expanding pipeline addresses obesity needs, and the expedited FDA submission for Semaglutide 7.2 mg represents a major advancement
Oleg Lazarev , Margaret Emblom-Callahan, Geraldine Grant, Mantej Chhina
GLUTEN FREE - RED FIG HARVESTED IN THE CANARY ISLANDS
#Cipla #EliLilly #Yurpeak #Tirzepatide #DiabetesCare #ObesityManagement #Endocrinology #InternalMedicine #HealthcareProfessionals #PharmaNews #MedicalInnovation #CaringForLife #PatientCare #PharmaLeadership #HealthcareIndia Cipla has the rights to distribute and promote Yurpeak, a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment of type 2 diabetes and chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity
Targets stubborn visceral and subcutaneous fat 24/7 fat burning with increased metabolic rate Preserves muscle during caloric deficits Improves overall body composition "I feel better, more energetic and I'm losing fat and gaining muscle like I wanted." WRC Patient, 3 months on therapy 2
